ライフサイエンスコーパス: fluorescein

1 ic organelles, F-actin, keratin, and soluble fluorescein.

2 rofiles red-shifted nearly 50 nm compared to fluorescein.

3 anaphylactic reaction after the injection of fluorescein.

4 f the laboratory analysis by the presence of fluorescein.

5 ating PM disruption and cytosolic release of fluorescein.

6 larizations collapsed after the injection of fluorescein.

7 d the interference of laboratory analyses by fluorescein.

8 oscopy to monitor BBB permeability of sodium fluorescein (376 Da), Alexa Fluor (643 Da), and fluoresc

9 (MBs) by exploiting the dual-fluorescence of fluorescein (6-FAM) and hydoxynaphthol blue (HNB).

10 mination including color fundus photography, fluorescein and indocyanine green angiographies, spectra

11 ecialists evaluated color fundus photographs fluorescein and indocyanine green angiography images to

12 n, fundoscopy, optical coherence tomography, fluorescein and indocyanine green angiography in a 66 ye

13 gs of tumor basal diameter and thickness and fluorescein and indocyanine green angiography were no di

14 est for color vision, quality of life (QoL), fluorescein and indocyanine green angiography, and optic

15 h short-wavelength autofluorescence, SD-OCT, fluorescein and indocyanine green angiography.

16 CT angiography, fundus autofluorescence, and fluorescein and indocyanine green angiography.

17 Small-molecule fluorophores, such as fluorescein and rhodamine derivatives, are critical tool

18 FCP-1 links fluorescein and rhodamine dyes through a Tris[(2-pyridyl

19 were first discovered in the 1800s, and the fluorescein and rhodamine scaffolds have been known for

20 of the antibody), respectively, labeled with fluorescein and rhodamine.

21 n, and propranolol) and two model compounds (fluorescein and sulforhodamine B) from porous media foll

22 to existing methods using simulated spectra, Fluorescein and TAMRA dye mixtures as a zero FRET contro

23 correlate with fluorophotometry: OSDI, TBUT, fluorescein, and lissamine.

24 tained for acetazolamide, riboflavin, sodium fluorescein, and theophylline in 2-hydroxyethyl methacry

25 ncreased by ~ 10% for a small solute, sodium fluorescein, and ~ 120% for larger solutes, BSA and Dex-

26 field testing, fundus photography (FP), OCT, fluorescein angiogram (FA), and fundus autofluorescence

27 Fluorescein angiogram characteristics included staining

28 ed and the amount of retinal nonperfusion on fluorescein angiogram was calculated.

29 Fluorescein angiograms (FA) and OCT were evaluated by an

30 of GA in digital color photographs (CPs) and fluorescein angiograms (FAs) taken at baseline and years

31 d vascular patterns than were visible on the fluorescein angiograms although within a more posterior

32 Baseline fundus fluorescein angiograms and OCT images were graded for ch

33 retinal periphery that were obscured in the fluorescein angiograms by fluorescein staining from unde

34 Fluorescein angiograms of the affected and fellow eyes w

35 Fluorescein angiograms were examined by 2 experts to doc

36 gram compared with that shown in intravenous fluorescein angiograms.

37 ch MIOCT angiograms and clinically indicated fluorescein angiograms.

38 signal regions led to faster development of fluorescein angiographic patterns (3.1-fold; p = 0.02).

39 ns showed transient or persistently improved fluorescein angiographic signal (11.2-fold; p = 0.014).

40 To correlate the fundoscopic, fluorescein angiographic, oximetric, and optical coheren

41 All images from subjects with same-day UWF fluorescein angiography (FA) and color imaging were eval

42 Concurrent fluorescein angiography (FA) and indocyanine green angio

43 Color, fluorescein angiography (FA) and OCT images acquired at

44 V detection compared to the gold standard of fluorescein angiography (FA) and OCT was determined for

45 ting, refraction, dilated fundus examination fluorescein angiography (FA) and SD-OCT (spectral Domain

46 Fluorescein angiography (FA) and SS-OCTA imaging (PLEX E

47 Patients were imaged longitudinally with fluorescein angiography (FA) and swept-source (SS) OCT a

48 Our aim was to describe the fluorescein angiography (FA) findings in patients who re

49 CTA) was compared with ultrawide-field (UWF) fluorescein angiography (FA) for evaluating neovasculari

50 Baseline fluorescein angiography (FA) images of all CATT study ey

51 Color fundus photography and fluorescein angiography (FA) images were used to create

52 evaluated digital color fundus photographs, fluorescein angiography (FA) images, and optical coheren

53 ging was compared with ultra-widefield (UWF) fluorescein angiography (FA) imaging to better understan

54 Fluorescein angiography (FA) is a procedure used to imag

55 Fluorescein angiography (FA) may become necessary to eva

56 cystoid macular edema (CME), and the highest fluorescein angiography (FA) score during the course of

57 Fluorescein angiography (FA) showed nonspecific retinal

58 Fluorescein angiography (FA) showed very severe leakage

59 Fluorescein angiography (FA) was acquired at baseline, 3

60 Ultra-widefield fluorescein angiography (FA) was also performed when cli

61 Fluorescein angiography (FA) was performed in 113 eyes,

62 c retinopathy (PDR) on ultra-widefield (UWF) fluorescein angiography (FA) were identified and compare

63 Digital retinal imaging and fluorescein angiography (FA) were performed at an averag

64 mic examination, OCT angiography (OCTA), and fluorescein angiography (FA) with widefield imaging.

65 examination including structural OCT, OCT-A, fluorescein angiography (FA), and indocyanine green angi

66 atients underwent SS OCT angiography (OCTA), fluorescein angiography (FA), and indocyanine green angi

67 ollow-up morphology on digital color images, fluorescein angiography (FA), and optical coherence tomo

68 We performed following examinations: fluorescein angiography (FA), B-scan ultrasound, spectra

69 ged with optical coherence tomography (OCT), fluorescein angiography (FA), blue fundus autofluorescen

70 Imaging features obtained using fluorescein angiography (FA), indocyanine green angiogra

71 uipment, including color fundus photography, fluorescein angiography (FA), OCT, and PAM, was used to

72 raphy, fundus photography, autofluorescence, fluorescein angiography (FA), optical coherence tomograp

73 ed by optical coherence tomography (OCT) and fluorescein angiography (FA).

74 art, optical coherence tomography (OCT), and fluorescein angiography (FA).

75 herence tomography angiography (SS-OCTA) and fluorescein angiography (FA).

76 O and CRAO were established as affirmed with fluorescein angiography (FA).

77 l records of patients with nAMD confirmed on fluorescein angiography (FA).

78 Fundus fluorescein angiography (FAG) revealed central hypofluor

79 studied using fundus imaging, SS-OCT, fundus fluorescein angiography (FFA), and indocyanine green ang

80 raphy (ERG), fundus photography (FP), fundus fluorescein angiography (FFA), and optical coherence tom

81 The findings were compared with fundus fluorescein angiography (FFA), and swept-source optical

82 ical coherence tomography (OCT), intravenous fluorescein angiography (IVFA), indocyanine-green angiog

83 Pretreatment ocular characteristics on fluorescein angiography (lesion type, area of neovascula

84 s with DR that had undergone ultra-widefield fluorescein angiography (UWFA) with associated color pho

85 inical study to determine if ultra-widefield fluorescein angiography (UWFA), spectral-domain optical

86 Ultra-widefield fluorescein angiography (UWFA; California Optos [Optos,

87 wed for abnormal findings on ultra-widefield fluorescein angiography (UWFFA) and OCT.

88 ing techniques, including widefield imaging, fluorescein angiography (with peripheral sweeps), and OC

89 Fluorescein angiography after bevacizumab for ROP reveal

90 Widefield fluorescein angiography analysis of 95 eyes (53 patients

91 Fluorescein angiography and fundus autofluorescence were

92 Retinal fluorescein angiography and optical coherence tomography

93 Retinal perfusion status was evaluated by fluorescein angiography based on the presence or absence

94 a monthly basis with fundus photography and fluorescein angiography before and after each IAC inject

95 Fluorescein angiography can be an important tool in eval

96 This information in combination with ICG and fluorescein angiography can help to optimize direct lase

97 ocular coherence tomography (OCT), and with fluorescein angiography confirmation.

98 Retinal fluorescein angiography demonstrated delayed perfusion a

99 Fluorescein angiography demonstrated peripheral retinal

100 An 86-year old Caucasian woman undergoing fluorescein angiography due to suspected peripapillary n

101 iography, indocyanine green angiography, and fluorescein angiography for comparison with the patholog

102 Fluorescein angiography had the highest accuracy (97%, 3

103 Fluorescein angiography has shown potentially serious an

104 HARBOR analyzed color fundus photography and fluorescein angiography image data.

105 Ultra-widefield fluorescein angiography images were obtained in 63 eyes

106 Widefield fluorescein angiography images were reviewed for periphe

107 ens, and retinal vasculature was examined by fluorescein angiography in WT and Fabry rats.

108 Fluorescein angiography is an important and frequently u

109 Fluorescein angiography is important in assessing vascul

110 gonioscopy, dilated fundus examination, and fluorescein angiography is recommended in infants with s

111 Intravenous fluorescein angiography performed in 1 eye depicted the

112 us autofluorescence results, ultra-widefield fluorescein angiography results, and indocyanine green a

113 Fluorescein angiography revealed active leakage, especia

114 Fluorescein angiography revealed delayed retinal arteria

115 Fluorescein angiography revealed early hypofluorescence

116 e large choroidal vessels and optic atrophy; fluorescein angiography revealed gradual restoration of

117 the anterior chamber (P = .007); the highest fluorescein angiography score (P = .011); age (P < 0.001

118 Fluorescein angiography showed a late hyperfluorescence

119 Fluorescein angiography showed bilateral dilated, ectati

120 Fluorescein angiography showed no definite leakage in an

121 Fluorescein angiography showed saccular lesions that fil

122 ts (n = 6 eyes of 3 patients) with widefield fluorescein angiography showed several retinal vascular

123 eld fundus imaging including pseudocolor and fluorescein angiography using an Optos 200Tx device.

124 Fluorescein angiography was not found to be associated d

125 Fluorescein angiography was performed in 17 of 43 diabet

126 Optical coherence tomography (OCT) and fluorescein angiography were also obtained at some visit

127 l-domain OCT, near-infrared reflectance, and fluorescein angiography were investigated.

128 ace between two domains (i.e. funduscopy and fluorescein angiography) provides an unrivaled way for t

129 Fluorescein angiography, a combination of 2 OCT protocol

130 cs, such as early onset, cuticular drusen on fluorescein angiography, and family history of AMD.

131 ocolor photography, fundus autofluorescence, fluorescein angiography, and indocyanine green angiograp

132 ocols, and included CFP, multicolor imaging, fluorescein angiography, and indocyanine green angiograp

133 domain OCT, autofluorescence imaging, fundus fluorescein angiography, and OCT angiography (OCTA) were

134 etails and images (color fundus photography, fluorescein angiography, and OCT) for all investigator-d

135 anibizumab, bevacizumab, fundus photographs, fluorescein angiography, and optical coherence tomograph

136 r pigment (MP), OCT, blue light reflectance, fluorescein angiography, as well as fundus photography,

137 had multimodal imaging (fundus photography, fluorescein angiography, autofluorescence, and spectral-

138 Fluorescein angiography, especially with widefield capab

139 In 1 patient imaged with fluorescein angiography, focal segments of retinal venul

140 in all patients and were hyperfluorescent on fluorescein angiography, hypofluorescent on ICG angiogra

141 e were imaged with autofluorescence imaging, fluorescein angiography, indocyanine green angiography,

142 h various combinations of color photography, fluorescein angiography, indocyanine green angiography,

143 omplete ophthalmologic examination including fluorescein angiography, indocyanine green angiography,

144 methods such as enhanced depth imaging-OCT, fluorescein angiography, indocyanine green angiography,

145 erwent indocyanine green angiography, fundus fluorescein angiography, mesopic microperimetry, and mul

146 as identified on dilated fundus examination, fluorescein angiography, or both in 11 eyes of 6 patient

147 andard 7-field stereo fundus photography and fluorescein angiography, respectively.

148 graphy, fundus autofluorescence, intravenous fluorescein angiography, spectral-domain OCT and OCT ang

149 gathering included fundus color photographs, fluorescein angiography, spectral-domain optical coheren

150 ging findings, including fundus photography, fluorescein angiography, spectral-domain optical coheren

151 Serious complications can occur with fluorescein angiography, such as an anaphylactic reactio

152 ion when choosing the healthcare setting for fluorescein angiography, such as the immediate availabil

153 uate retinal capillary blood flow instead of fluorescein angiography, the reflectance pattern of bloo

154 or photos, optical coherence tomography, and fluorescein angiography.

155 with resolved macular edema, and leakage on fluorescein angiography.

156 al vasculature with lower risk and cost than fluorescein angiography.

157 al iris vessels, not distinct on intravenous fluorescein angiography.

158 were more distinct on OCTA than intravenous fluorescein angiography.

159 linical examination, fundus photography, and fluorescein angiography.

160 etinal capillary flow data in the absence of fluorescein angiography.

161 ptical coherence tomography (OCT) and fundus fluorescein angiography.

162 4, and vascular permeability was analyzed by fluorescein angiography.

163 e choroidal neovascularization at week 12 on fluorescein angiography.

164 (SD OCT), fundus autofluorescence (FAF), and fluorescein angiography/indocyanine green (ICG) angiogra

165 giography, fundus autofluorescence (FAF) and fluorescein-angiography (FA).

166 Subsequent fluorescein aqueous angiography was utilized to query al

167 , we developed sensitive assays that use the fluorescein arsenical dye FlAsH (fluorescein arsenical h

168 nergy transfer (FRET) approach using a small fluorescein arsenical hairpin (FlAsH) targeted to a shor

169 hat use the fluorescein arsenical dye FlAsH (fluorescein arsenical hairpin binder) to detect soluble

170 To overcome this limitation, we develop the Fluorescein Arsenical Hairpin Binder- (FlAsH-) based FRE

171 rgy transfer (BRET)-based and conformational fluorescein arsenical hairpin-BRET sensors coupled with

172 e of the device was initially performed with fluorescein as a test molecule.

173 ined value with a standard measure involving fluorescein as reference.

174 cular weight of either 15 kDa or 52 kDa, and fluorescein as the mock drug.

175 ied the real-time intracellular release of a fluorescein at a single-cell resolution.

176 nt a new family of readily functionalizable, fluorescein-based voltage-sensitive fluorescent dyes (sa

177 dation of dihydrorhodamine 123, AAPH-induced fluorescein bleaching and hypochlorite-induced fluoresce

178 uorescein bleaching and hypochlorite-induced fluorescein bleaching.

179 Fluorescein concentration of DED and normal patients sho

180 criptase quantitative PCR and measurement of fluorescein concentrations (doped into the nebulized aer

181 Different fluorescein concentrations in CaSO4 beads were evaluated

182 ss the capillary bed with the small molecule fluorescein, concomitant with reactive astrocytosis.

183 adhesive-dentin interface were covered with fluorescein-conjugated gelatin and observed with a multi

184 nhibited (40-70% inhibition) the cleavage of fluorescein-conjugated gelatin by MMP-2, but not MMP-9.

185 Fluorescence intensity emitted by hydrolyzed fluorescein-conjugated gelatin was quantified, and the a

186 0.05) for the reaction of MMP-2 cleavage of fluorescein-conjugated gelatin.

187 r "ELISA"), to small molecule ligands, using fluorescein conjugates and antifluorescein antibodies as

188 asculature without the need for injection of fluorescein contrast dye.

189 eye: TBUT <=10 s, Schirmer score <= 5 mm and fluorescein corneal staining >= grade 1.

190 ctive tests: tear film break-up time (TBUT), fluorescein corneal staining (FL/S) and Schirmer test.

191 0 induced an increase in the fluorescence of fluorescein diacetate (FDA) by 30 and 42%, suggesting a

192 We assessed sputum microscopy with fluorescein diacetate (FDA, evaluating M. tuberculosis m

193 ha were measured as proliferation by carboxy-fluorescein diacetate succinimidyl ester dye dilution an

194 esophageal stent to demonstrate delivery of fluorescein diacetate, using applied tension, to an ex v

195 The approach is based on embedding fluorescein dilaurate (FDL), a fluorogenic ester substra

196 Compared with the use of 3,6-fluorescein diphosphate as a signal reporter in an ALP-l

197 a detection limit of 613 +/- 13 pM for CE of fluorescein disodium salt solution in borate buffer.

198 e Suzuki cross-coupling of the electron-poor fluorescein ditriflate with the electron-rich boronic ac

199 ed oxidative cleavage decreases FRET between fluorescein donor and rhodamine acceptor.

200 alized with two different dyes, respectively fluorescein (donor) and eosin (acceptor), which form a s

201 itoring the enzymatic cohydrolysis of FDL to fluorescein during enzymatic hydrolysis of the polyester

202 A fluorescein dye labeled GO quenches the truncated aptame

203 Fluorescein dye was then placed into both eyes, rinsed w

204 unctionalized nopoldiol reagent labeled with fluorescein dye.

205 oltage imaging at wavelengths beyond typical fluorescein excitation and emission.

206 n of single stranded DNA labeled with either fluorescein (FAM) or tetramethylrhodamine (TAMRA) with a

207 rs and detachments (RDs), retinoschisis, and fluorescein findings.

208 e of three model compounds, ibuprofen (IBU), fluorescein (FLU), and 4',6-diamidino-2-phenylindole (DA

209 Fluorescein fundus angiography soon after cutting the PC

210 ophthalmoscopy, color fundus photography and fluorescein fundus angiography, before and immediately a

211 t an interference with laboratory testing by fluorescein in this patient and summarize the literature

212 kHz and yield detection limits of 400 nM for fluorescein in water.

213 el was evaluated using a fluorescent tracer (fluorescein) incorporated in the carrier materials calci

214 Mechanical properties of fluorescein-incorporated beads were analyzed.

215 s to a vascular evaluation by a simultaneous fluorescein/indocyanine green angiography.

216 d directly at the valve outlet by monitoring fluorescein injection profiles with laser-induced fluore

217 Conjugation of fluorescein isothiocyanate (10.86 +/- 0.94 percentage in

218 the dyes in their free isothiocyanate forms, fluorescein isothiocyanate (F-ITC) and tetramethylrhodam

219 arch on feasibility, removal of unconjugated fluorescein isothiocyanate (FITC) after fluorescent labe

220 oring of the bioconjugation reaction between fluorescein isothiocyanate (FITC) and a model protein il

221 Zein was tagged with fluorescein isothiocyanate (FITC) and made into nanopart

222 ing of the film, after a post-treatment with Fluorescein Isothiocyanate (FITC) labeled 8-OHdG antibod

223 reened for their ability to inhibit anti-CR3-fluorescein isothiocyanate (FITC) staining of human neut

224 permeability, as measured by the passage of fluorescein isothiocyanate (FITC)-dextran through endoth

225 d DSS plus ATB (DSS+ATB) was demonstrated by fluorescein isothiocyanate (FITC)-dextran translocation

226 e for matrix metalloproteinase-2/9 activity, fluorescein isothiocyanate (FITC)-gelatin.

227 Fluorescein isothiocyanate (FITC)-labeled control siRNA

228 ching technique, diffusion coefficients D of fluorescein isothiocyanate (FITC)-pepsin were measured i

229 and are covalently labeled with pH-sensitive fluorescein isothiocyanate (FITC).

230 ocyanate-labeled IAV in the presence of anti-fluorescein isothiocyanate antibody also resulted in vir

231 For in vivo analyses, we used fluorescein isothiocyanate contact hypersensitivity and

232 r PEG-like molecules (CH3-PEG5K-FITC (FITC = fluorescein isothiocyanate) and eight-arm PEG20K-FITC) w

233 smural sections of jejunum were stained with fluorescein isothiocyanate-conjugated isolectin-B4 for e

234 ectrical resistance and paracellular flux of fluorescein isothiocyanate-dextran (4 kDa) together with

235 electrical resistance, paracellular flux of fluorescein isothiocyanate-dextran 4 kDa, and mRNA expre

236 sed intestinal permeability, as indicated by fluorescein isothiocyanate-dextran absorption and serum

237 acellular permeability was measured by using fluorescein isothiocyanate-dextran flux.

238 Intestinal permeability was investigated by fluorescein isothiocyanate-dextran uptake assay, quantit

239 istance), reduced paracellular permeability (fluorescein isothiocyanate-dextran), and prevented vascu

240 by jugular vein infusion of (125)I-fibrin or fluorescein isothiocyanate-fibrin labeled emboli in anes

241 vascular permeability to Evans blue dye and fluorescein isothiocyanate-labeled bovine serum albumin

242 ransepithelial electrical resistance (TEER), fluorescein isothiocyanate-labeled dextran 4kDa (FD4) fl

243 Exposure of AMs to fluorescein isothiocyanate-labeled IAV in the presence o

244 4) was determined by co-immunoprecipitation, fluorescein isothiocyanate-probing, and surface plasmon

245 on revealed the specific binding capacity of fluorescein isothiocyanate-RamAb to VEGFR-2, and no diff

246 Here, we highlight the use of fluorescein isothiocyanate-tagged ChNPs as an invaluable

247 nscription during mitosis, as confirmed with fluorescein isothiocyanate-uridine 5'-triphosphate label

248 molecule Rhodamine B (RhB) and model protein Fluorescein isothiocynate (FITC) Bovine Serum Albumin (B

249 Fluorescein labeled folic acid was used for flow cytomet

250 y high-affinity binding to standby-competent fluorescein-labeled +42 mRNA, but not to mRNAs that lack

251 uent was continuously contacted with soluble fluorescein-labeled Fc-binding ligands to produce an imm

252 completely, thereby conferring protection to fluorescein-labeled Micrococcus lysodeikticus from lysoz

253 luorescence at deeper layers of the skin for fluorescein-labeled siRNA-CYnLIP than solution.

254 the emission spectra of eosin (tetrabromine fluorescein) lake mixed with lead or zinc white at lower

255 Fluorescein leak, measured by CLE, improved only in thos

256 Submacular fluid without fluorescein leakage and unresponsive to conventional tre

257 of leakage on FA and 1 eye had questionable fluorescein leakage.

258 eight bispecific adapters, each comprised of fluorescein linked to a different tumor-specific ligand,

259 skin burn severity using a topically applied fluorescein-loaded liquid bandage and an unmodified comm

260 conjugation and delivery of the model probe fluorescein-maleimide and the medicinal agent paclitaxel

261 ated by impregnating 2.5 muL (0.285 nmol) of fluorescein mercury acetate (FMA) onto the surface of a

262 the low molecular weight fluorophore sodium fluorescein (NaFl), whereas diet-induced insulin resista

263 owed previously undescribed features such as fluorescein-negative intraretinal cystic changes, choroi

264 as assessed using CaSO4 beads that contained fluorescein or antibiotics and were pre-coated with huma

265 Fluorescein penetration (0.09%) was less than rhodamine

266 No fluorescence was detectable from fluorescein PMs, indicating quenching.

267 Following incubation of L929 cells with fluorescein PMs, there was a gradual increase in intrace

268 concentration had no influence on short-term fluorescein release and pre-coating of beads with body f

269 scent guests, namely coumarin 1, coumarin 4, fluorescein, [Ru(bpy)3 ]Cl2 , and rhodamine B, can be en

270 of the water-soluble fluorescent dye sodium fluorescein salt and the drug doxycycline.

271 is genetically fused to a high-affinity anti-fluorescein scFv antibody fragment (scFvFITC).

272 rtunity for simultaneous imaging with GFP or fluorescein sensors upon single excitation.

273 s -1.14 +/- 1.68 seconds, P < .001), corneal fluorescein staining (-0.62 +/- 0.30 vs 0.19 +/- 0.37, P

274 erse events, and efficacy, including corneal fluorescein staining (CFS) score.

275 The main efficacy end points were corneal fluorescein staining (CFS), tear film break-up time (TBU

276 outcome at 3 months and limbal conjunctival fluorescein staining (r = 0.67, P = .006), and limbal co

277 re obscured in the fluorescein angiograms by fluorescein staining from underlying, preexisting laser

278 ed healing status conventionally (<0.5 mm of fluorescein staining in the greatest dimension of the le

279 reases in the postoperative LG scores and in fluorescein staining post ptosis surgery compared with t

280 thout anesthesia) >/=1 and </=10 mm, corneal fluorescein staining score >/=2.0 (0-4 scale), eye dryne

281 orrelation was seen between OSDI and corneal fluorescein staining scores (rs = 0.67, P = .01).

282 infiltration of Th17 cells and lower corneal fluorescein staining scores compared with saline-treated

283 points including total and subregion corneal fluorescein staining, conjunctival staining, visual anal

284 Schirmer test 2, tear break-up time (TBUT), fluorescein staining, Lissamine-green staining (LG).

285 045) but not with tear breakup time, corneal fluorescein staining, or ocular medications used by pati

286 underwent clinical examination with corneal fluorescein staining, Schirmer 1 tear test, assessment o

287 ondrial membrane potential readings, corneal fluorescein staining, tear volume concentrations, tear f

288 ependent assays (CD154 detection and carboxy-fluorescein succinimidyl ester dilution assays) and 9 in

289 d by fluorescence polarization analysis of a fluorescein-tagged peptide corresponding to pol beta res

290 Here we report the use of a fluorescein-tagged peroxisomal targeting sequence peptid

291 same time with biotin/digoxigenin or biotin/fluorescein tags, respectively.

292 in, was generated to show utility beyond the fluorescein test molecule.

293 novel chemical probes, ubiquitin C-terminal fluorescein thioesters UbMES and UbFluor, to qualitative

294 We identified fluorescein-trehalose analogues that are metabolically i

295 A detection limit of 12 pM fluorescein was achieved when sampling 20 droplets, and

296 Fluorescein was encapsulated stably in PMs of mean diame

297 al reduction of a quinone in the presence of fluorescein was selected to both generate and monitor a

298 the working principle for the model compound fluorescein, where the organic solvent DMSO is exchanged

299 terns at the 3' and 6' positions, similar to fluorescein, while simultaneously possessing excitation

300 tamol, ibuprofen, tamoxifen, BAY 11-7082 and fluorescein, with accuracy on the scale of micrograms pe